The cancer trials utilize RNA‐knockdown ASOs targeted at oncogenes like B‐cell lymphoma 2 (NCT04072458) and genes associated with cancer cell growth and proliferation mediators like growth factor receptor‐bound protein 2 (NCT02781883 and NCT04196257) and androgen receptor (NCT03300505). Here, AR is linked to cancer.